Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
     
  • Novartis remains committed to ongoing research and development for COVID-19
     
  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

Basel, June 19, 2020 — Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made …

/by

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

 

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made

 

  • Novartis remains committed to ongoing research and development for COVID-19

 

  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

 

Basel, June 19, 2020 — Novartis has made the decision to stop and …

/by